翰宇藥業:擬投建5條自動化醫用口罩生產線
格隆匯2月10日丨翰宇藥業(300199.SZ)公佈,隨着新型冠狀病毒感染肺炎疫情在全國範圍的出現,全國多省、市進入一級響應狀態,醫療防護用品嚴重短缺,公司為貫徹落實國務院及地方政府關於全力加快疫情防控物資生產的部署,根據深圳市工業和信息化局《關於加快採購生產設備及提高產能的函》、天水市工業和信息化局《關於加快一次性醫用口罩生產線項目建設的函》要求,擬在全資子公司甘肅成紀生物藥業有限公司(“成紀藥業”或“子公司”)的現有場地設施基礎上,投資建設5條自動化醫用口罩生產線。全力支持解決醫用防護物資生產供應不足的問題,填補天水市及其周邊地區醫用防護用品生產企業的空白。此次成紀藥業醫用口罩生產線改建項目計劃投資金額約1862萬元人民幣,項目完全達產後預計醫用口罩年產量約2億隻,投資所需資金來源為公司自籌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.